Arvinas (ARVN) shares soared after releasing interim data and on 12/9 in the OptionsHawk Trading Hub we identified the call buy as well as the catalyst:

“Arvina (ARVN) stock and IV popping as December $35 calls open 2714X at $2.25. ARVN follow up, calls look to be playing this catalyst, Phase 1 trials evaluating ARV-110 and ARV-471 in advanced metastatic prostate and breast cancer settings, respectively, due soon”

We also caught a call buyer back on 11/9: “Arvinas (ARVN) stock replacement opens 1000 December $35 calls $2.50″

Talk about a well-timed trade…